普米克令舒治疗儿童咳嗽变异性哮喘疗效观察

The curative effect of pulmicort inhalation on children with cough variant asthma

目的探讨布地耐德吸入剂普米克令舒治疗儿童咳嗽变异性哮喘的疗效。方法57例儿童咳嗽变异性哮喘(CVA)随机分成两组,令舒组22例予普米克令舒0.5 mg b id吸入,辅舒酮组35例予丙酸氟替卡松吸入剂125μg b id吸入,分别于治疗后1、4、8周评价其临床症状评分及控制率变化。结果治疗后1周,令舒组与辅舒酮组相比,患儿临床症状综合评分及控制率均较后者好(P<0.05);治疗4周及8周后差异无显著性。结论对于咳嗽变异性哮喘普米克令舒较辅舒酮能更快地改善患儿症状和达到控制。

Aim To study the curative effect of Pulmicort inhalation on children with cough variant asthma. Methods 57 children with cough variant asthma（CVA） were randomly divided into two groups. 22 Children in the treatment group inhale Pulmicort. While 35 children in the treatment group inhale fluticasone propinat. To evaluate the clinical symptom scores and control the rates of change respectively in the 1,4,8 weeks after treatment. Results After 1 week of treatment, so that the pulmicort group of children with comprehensive clinical score and control the rate were observed better than the fluticasone propinat （ P 〈 0. 05 ） ; and there were no difference after 4 and 8 weeks. Conclusion Pulmicort has positive effect on cough variant asthma, and more quickly to improve symptoms and meet control than Flixotide.